A Mixture of Lactobacillus fermentum HFY06 and Arabinoxylan Ameliorates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice.

OBJECTIVE: Colitis is one of the main gastrointestinal diseases threatening human health.
MATERIALS AND METHODS: In this study, a synbiotic composed of arabinoxylan (AX) and Lactobacillus fermentum HFY06 was tested to determine its ability to relieve dextran sulfate sodium (DSS)-induced colitis.
RESULTS: The experimental results showed that the synergistic effect of AX and L. fermentum HFY06 alleviated the weight loss of DSS-mediated colitis mice and lowered the disease activity index (DAI) score. Determination of biochemical indicators found that the synbiotic composed of AX and L. fermentum HFY06 increased the body's antioxidant capacity and reduced inflammation. The histopathological examination results showed that the colonic crypts of the mice in the model group were disordered, goblet cells were lost, and the mucous membrane was severely damaged. However, the combination of AX and L. fermentum HFY06 can significantly reverse the histopathological changes in the colon mediated by DSS. The gene expression of colon tissue was further determined, and the results showed that the synergistic effect of AX and L. fermentum HFY06 inhibited the activation of the NF-κB signaling pathway, downregulated the mRNA expression levels of nuclear factor-κB-p65 (NF-κBp65), upregulated the mRNA expression of NF-κB inhibitor-α (IκB-α), inhibited the release of cytokines tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), and cyclooxygenase (COX-2), and exerted anti-colitis effects.
CONCLUSION: This study shows that the synbiotic composed of AX and L. fermentum HFY06 has the potential to prevent and treat colitis.

Introduction

Colitis is an idiopathic, chronic inflammatory disorder. The disease usually affects the rectum, but can also involve any part of the colon.1,2 In clinical terms, chronic abdominal pain and bleeding are the most typical symptoms. The incidence rate has been increasing in the past 20 years, but its mechanism is not clear. Genetic factors, environmental factors, microbial factors, and other factors can lead to the formation and development of diseases.3,4

The intestinal microecosystem is the largest of the human body. Under normal circumstances, there are a large number of bacteria distributed in the intestine. These flora constitute a microbial barrier to provide energy and nutrition, protect the integrity of the intestinal structure, and maintain the stability of the intestinal immune system.5 Increasing evidence shows that gut microbes directly affect the initiation and development of colitis.6,7 For such patients, supplementation with probiotics is beneficial to the recovery and reconstruction of the intestinal flora, which in turn is beneficial for disease amelioration. There are three main methods that can be used to consume supplemental probiotics are: (i) directly consume supplemental probiotics, (ii) consume prebiotics to indirectly promote the proliferation of their own beneficial flora, or (iii) consume supplemental synbiotics, which are a combination of probiotics and prebiotics.8,9

Probiotics are a type of active microorganism that can be orally consumed and then grown in the intestinal tract to regulate the number and types of intestinal flora, thereby further restoring the ecological balance between intestinal microorganisms.10 Probiotics are derived from food and are not pathogenic to humans, and they have high tolerance to gastric acid and bile. They can also adhere to the human intestinal mucosa and regulate the gastrointestinal flora, thereby enhancing the intestinal and system immunity. They can alleviate the symptoms of ulcerative colitis. The probiotics currently studied are mainly Bifidobacterium,11 Lactobacillus,12 and yeast.13 Probiotics are sometimes affected by the colonization ability of the flora and the survival rate of viable bacteria. Prebiotics are not digested or absorbed by the host, but can selectively promote the metabolism and proliferation of one or more beneficial bacteria in the body.14 Prebiotics can also enhance the functional activity of intestinal and bodily immune cells (macrophages, dendritic cells, T cells, B cells, and natural killer cells), and regulate immune cells to secrete cytokines and antibodies to exert direct immunoregulation.15,16 A study by Kangliang Shen et al found that a synbiotic composed of Bifidobacterium infantis and prebiotic xylo-oligosaccharides reduced the level of inflammation in mice with colitis, downregulated the pro-inflammatory cytokines TNF-α and IL-1β, upregulated anti-inflammatory cytokine IL-10, and also enhanced the levels of tight junction proteins ZO-1, occludin, and claudin-1 in the intestine, thereby enhancing the colonic epithelial barrier integrity.17 The results indicate that synbiotics are a promising dietary supplement or functional food. Arabinoxylan (AX), a new type of prebiotic, can specifically promote the proliferation of probiotics. Lactobacillus fermentum HFY06 is a strain that was isolated from yak yogurt that contains numerous beneficial bacteria. However, the effect of a synbiotic composed of HFY06 and AX on acute ulcerative colitis in mice is unclear.

Therefore, this study hypothesized that the synbiotics composed of HFY06 and AX can effectively alleviate acute ulcerative colitis in mice. The acute mouse colitis model induced by dextran sulfate sodium (DSS) was established by body weight analysis, serum inflammatory factor level, body oxidative stress level, colon tissue section, and colon tissue NF-κ B signaling pathway-related gene expression to determine its possible preventive mechanism in colitis. To the best of our knowledge, this is the first study on the synbiotic composed of HFY06 and AX and its role and potential mechanism with regard to colitis.

Materials and Methods

Material/Strain Source

L. fermentum HFY06 was isolated from a unique yak yogurt of Sichuan, China, and is stored in the China General Microbial Culture Collection, Beijing, China (No. 16636). The control strain used was Lactobacillus delbrueckii subsp. Bulgaricus (No. 1.16075). The purity of arabinoxylan (AX) was greater than 95% (No. 120601b). The ratio of arabinose:xylose = 38/62.

Establishment of an Animal Model

Fifty C57BL/6J male mice, 8 weeks old, were purchased from the Experimental Animal Center of Chongqing Medical University, Chongqing, China. The mice were randomly divided into 6 groups, namely the (i) normal group, the (ii) model group, the (iii) AX group, the (iv) HFY06 group, the (v) AX+HFY06 combined group, and the (vi) LB (Lactobacillus delbrueckii subsp. Bulgaricus) group. Among them, the LB group was used for comparison with the HFY06 group, in order to compare the anti-inflammatory levels of commercial strains and L. fermentum HFY06 on high-fat diet mice. The experimental animals were adaptively fed for one week, with feeding conditions of 25 ± 2°C, with light and dark for 12 h. Drug intervention was performed after the adaptation week (Figure 1). First, preventive intervention was performed with drugs for 7 days. During this period, all mice drank ultrapure water. The AX group was gavaged with 250 mg/kg AX polysaccharide solution, the HFY06 group was gavaged with 1×1010 CFU of HFY06 bacterial suspension, and AX+HFY06 group was gavaged with AX polysaccharide solution (250 mg/kg) and HFY06 bacterial suspension (1 × 1010 CFU). The normal group and model group received normal saline via intragastric administration, and the intragastric dose for all mice was 0.2 mL. DSS induced acute colitis for 7 days. Except for the mice in the normal group, the mice in the other groups drank water containing 2.5% DSS. Drug intervention was performed at the same time, and the gavage dose was consistent with the prevention period. After the last administration, the mice were fasted for 12 h, retro-orbital sinus blood collection was performed, and then, the blood was centrifuged at 3000 r/min at 4°C for 10 min. The mice were euthanized by cervical dislocation, and the colon tissue of the mice was removed. The colon tissue and serum were stored in an ultra-low temperature freezer (−80°C) for further testing.

Figure 1

Animal experiment design.

Assessment of the Disease Activity Index (DAI)

After the induction of colitis, the mice in each group were weighed daily, and their stool characteristics, as well as the condition of fecal occult blood or gross blood in the stool were recorded. Fecal occult blood detection was performed using test paper and the benzidine method: first o-diaminodimethyl biphenyl was added to the stool sample, then 2% hydrogen peroxide was added, and the color change was observed. A color change to blue indicated that the stool sample was positive for occult blood. The disease activity index (DAI) score was obtained according to Tables 1,18 where DAI = (weight loss score + fecal consistency score + occult/gross bleeding)/3.

Table 1

Evaluation of the Disease Activity Index (DAI)

Stool Consistency	Occult/Gross Bleeding	Weight Loss (%)	Score
Normal	Normal (-)	0	0
Soft but shaped	Occult blood positive (+)	1–5	1
Semi loose stool	Occult blood (++)	>5–10	2
Loose stool	Gross bleeding (+++)	>10–15	3
Heavier loose stools	Gross bleeding(>+++)	>15	4

Note: DAI = (weight loss score+fecal consistency score+occult/gross bleeding)/3.

Measurement of Serum SOD, NO, and MDA Levels

After thawing the collected serum, a kit (Nanjing Institute of Bioengineering, Nanjing, China) was used to determine the amounts of superoxide dismutase (SOD), nitric oxide (NO), and malondialdehyde (MDA).

Measurement of Serum IL-1β, IL-6, IL-12, IFN-γ, TFN-α, and IL-10 Levels

After thawing the collected serum, a kit (Shanghai Enzyme Biotechnology Co., Ltd., Shanghai, China) was used to determine the amounts of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-12 (IL-12), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-10) in mouse serum.

Measurement of Colon MPO Activity

The colon tissue was removed from storage at −80°C and thawed, and the myeloperoxidase (MPO) enzymatic activity in the mouse colon tissue was measured according to the kit instructions (Nanjing Institute of Bioengineering, Nanjing, China).

Pathological Examination of Colon Tissue

Clean colon tissue without feces was removed from the newly dissected mice, and then immersed in 4% formaldehyde solution for fixation for 24 h. Then, dehydration, embedding, sectioning, H&E staining, and finally observing the pathological section under an optical microscope was performed, with subsequent obtainment of photographs.

Determination of mRNA Expression

The expression of iNOS, COX-2, TNF-α, IκB-α, and NF-κBp65 in the colon tissues of the five groups of mice was measured by quantitative polymerase chain reaction assay (Q-PCR). The mouse colon tissue was removed from storage at −80°C, and the total RNA was extracted by the TRIzol method. A nucleic acid analyzer was used to determine the RNA concentration, and when the purity value was between 1.8–2.0, subsequent tests were then performed. The RNA was reverse transcribed into cDNA using the Thermo Scientific Reverse Transcription Kit. Finally, the reverse-transcribed cDNA was used as a template, plus fluorescent dyes, and placed in a fluorescent quantitative PCR instrument for reaction. The reaction conditions used were as follows: 95°C for 60 s, 40 cycles of 95°C for 30 s, 65°C for 30 s, 72°C for 30 s, then, 95°C for 30 s, and 55°C for 35 s, with three parallel reactions for each sample. In the experiment, the β-actin gene was used as the internal reference gene, the -ΔΔCt value was calculated, and the 2−ΔΔCt relative quantification method was used to calculate the expression of each group of genes.19 The primer sequences are shown in Table 2.

Table 2

Primer Sequence List

Gene Name	Sequence
NF-κBp65	Forward: 5ʹ-ATGGCAGACGATGATCCCTAC-3’
	Reverse: 5ʹ-CGGAATCGAAATCCCCTCTGTT-3’
IκB-α	Forward: 5′-TGAAGGACGAGGAGTACGAGC-3′
	Reverse: 5′-TGCAGGAACGAGTCTCCGT-3′
iNOS	Forward: 5′-GTTCTCAGCCCAACAATACAAGA-3′
	Reverse: 5ʹ-GTGGACGGGTCGATGTCAC-3′-3’
COX-2	Forward: 5ʹ-GGTGCCTGGTCTGATGATG-3’
	Reverse: 5ʹ-TGCTGGTTTGGAATAGTTGCT-3’
TNF-α	Forward: 5ʹ-CAGGCGGTGCCTATGTCTC-3’
	Reverse: 5ʹ-GCTGCAACAGGGGGTAACAT-3’
β-actin	Forward: 5ʹ-CATGTACGTTGCTATCCAGGC-3’
	Reverse: 5ʹ-CTCCTTAATGTCACGCACGAT-3’

Statistical Analysis

The data are presented as the mean ± standard deviation. GraphPad Prism 7 software (Graph Pad Software Inc., La Jolla, CA, USA) was used for drawing. SPSS 17.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis, and the groups were compared by analysis of variance (ANOVA) followed by the Duncan multi-range test (p < 0.05).

Results

Anti-Inflammatory Level of Control Strain and L. fermentum HFY06

Table 3 shows the anti-inflammatory levels of the control strain (Lactobacillus delbrueckii subsp. Bulgaricus) and L. fermentum HFY06 on high-fat diet mice. The levels of pro-inflammatory factors IL-6, TNF-α, IFN-γ in serum of L. fermentum HFY06 mice were lower than those of control strain group mice, and the level of anti-inflammatory factor IL-10 was higher than that of control strain group. It shows that L. fermentum HFY06 has a stronger anti-inflammatory level than Lactobacillus delbrueckii subsp. Bulgaricus. Therefore, this study chose L. fermentum HFY06 as the research strain, to study the lipid-lowering effect of L. fermentum HFY06 combined with arabinoxylan on high-fat diet mice.

Table 3

Comparison of Anti-Inflammatory Effects Between Control Strain and L. fermentum HFY06 Strain

Group	IL-6 (ng/L)	IL-10 (ng/L)	TNF-α (ng/L)	IFN-γ (ng/L)
LB	54.20±3.17	230.16±9.36	424.71±12.82	90.42±6.99
HFY06	50.91±2.36	253.41±8.79***	334.21±55.45**	73.58±8.13*

Notes: The data are expressed as the mean ± SD. LB: 2.5% DSS with Lactobacillus delbrueckii subsp. Bulgaricus. HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the LB group.

Body Weight and DAI in Mice

The weight change in mice is an indicator of the severity of colitis. As shown in Figure 2A, the body weight of mice in the normal group steadily increased, while there was a significant decrease in body weight as the modeling time increased for the mice in the model group drinking 2.5% DSS, with weight loss beginning on the 3rd day. Some mice began to show fecal occult blood. On the 7th day, the body weight decreased to 81.56% of the original weight. After AX or L. fermentum HFY06, and AX and HFY06 synergistic intervention, the weight loss trend was alleviated. In particular, there was greater alleviation of weight loss of mice induced by DSS in the combined group of AX and HFY06, as compared to that of either AX or HFY06 alone.

Figure 2

Effect of AX combine L. fermentum HFY06 supplementation on (A) body weight and (B) DAI of mice.

As shown in Figure 2B, the DAI value of the mice in the model group reached 3.44 at 7 days. Compared with the model group, after the intervention of AX, HFY06, and AX and HFY06 combined, the DAI scores were 3, 2.89, and 2.33, respectively, which were 12.79%, 15.99%, and 32.27% lower than that of the model group. This shows that after treatment, the symptoms of colitis in mice abated, and a stronger effect was observed after treatment with the combination of HFY06 and AX.

Serum Levels of SOD, NO, and MDA in Mice

Compared with healthy mice, the SOD enzymatic activity in the serum of the model group mice significantly decreased, and the levels of NO and MDA significantly increased (p<0.05) (Table 4). There was significantly increased activity of SOD enzyme, and decreased NO and MDA in the synergistic intervention group receiving AX and HFY06, and there was a stronger effect observed with the combination of AX and HFY06 as compared to either AX and HFY06 alone.

Table 4

Serum Levels of SOD, NO and MDA in Mice

Group	SOD (U/mL)	NO (µmol/L)	MDA (nmol/mL)
Normal	55.69 ± 2.66c	6.18 ± 0.62a	1.51 ± 0.17a
Model	34.72 ± 2.60a	10.5 ± 0.32d	5.65 ± 0.48d
HFY06	36.61 ± 4.75a	8.08 ± 0.41c	2.57 ± 0.25b
AX	39.24 ± 4.41ab	8.45 ± 0.77c	3.30 ± 0.24c
AX+HFY06	44.52 ± 6.46b	7.19 ± 0.18b	1.47 ± 0.11a

Notes: The data are expressed as the mean ± SD. a–d Values in the same column with different letter superscripts indicate significant difference (p < 0.05). HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU), AX: 2.5% DSS with AX (200 mg/kg), AX+HFY06: 2.5% DSS with AX (200 mg/kg) and L. fermentum HFY06 (1.0 × 1010 CFU).

Serum Levels of IL-1β, IL-6, IL-12, IFN-γ, TNF-α, and IL-10 in Mice

As shown in Table 5, the levels of pro-inflammatory factors IL-1β, IL-6, IL-12, TNF-α, and IFN-γ in the normal group were the lowest, and the levels of anti-inflammatory factor IL-10 were the highest. The model group induced by DSS showed the opposite trend. The AX group, HFY06 group, and AX and HFY06 co-treatment group exhibited decreased levels of pro-inflammatory cytokines IL-1β, IL-6, IL-12, TNF-α, and IFN-γ, and increased levels of anti-inflammatory cytokine IL-10. For the pro-inflammatory factor IL-6 and the anti-inflammatory factor IL-10, the combined effect of AX and HFY06 was stronger than that of AX and HFY06 alone.

Table 5

Serum Levels of IL-1β, IL-6, IL-12, TNF-α, IFN-γ, and IL-10 in Mice

Group	IL-1β (ng/L)	IL-6 (ng/L)	IL-12 (ng/L)	TNF-α (ng/L)	IFN-γ (ng/L)	IL-10 (ng/L)
Normal	43.92±3.84a	43.68±6.82a	60.57±6.18a	237.57±34.37a	56.45±14.52a	374.07±40.38c
Model	66.98±8.30c	64.10±5.96c	72.32±5.06b	536.47±34.92c	91.92±6.62c	294.78±24.36a
HFY06	51.49±7.61ab	50.91±2.36ab	58.20±3.56a	334.21±55.45b	73.58±8.13b	253.41±8.79b
AX	55.27±5.81b	55.11±9.00b	58.01±8.67a	541.09±16.26c	69.72±14.18ab	297.08±34.41b
AX+HFY06	48.64±5.67ab	45.39±5.57a	55.58±4.05a	307.22±29.85b	63.51±7.19ab	264.41±18.43ab

Notes: The data are expressed as the mean ± SD. a–cValues in the same column with different letter superscripts indicate significant difference (p < 0.05). HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU), AX: 2.5% DSS with AX (200 mg/kg), AX+HFY06: 2.5% DSS with AX (200 mg/kg) and L. fermentum HFY06 (1.0 × 1010 CFU).

Colon MPO Activity in Mice

Figure 3 shows that compared with the normal group, after DSS induction in the model group, the MPO enzymatic activity in mouse colon tissue significantly increased (P <0.05), while the AX, HFY06, and AX and HFY06 combined treatment reduced the increase in MPO enzyme induced by DSS (P <0.05), especially for the combined group of AX and HFY06.

Figure 3

Effect of AX combine L. fermentum HFY06 supplementation on myeloperoxidase (MPO) enzyme activity in colon tissue. HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU), AX: 2.5%DSS with AX (200 mg/kg), AX+HFY06: 2.5% DSS with AX (200 mg/kg) and L. fermentum HFY06 (1.0 × 1010 CFU). Different letters above the histogram indicate significant differences (P<0.05).

Hepatic Pathological Observation

The results of the histopathological analysis of the colons of mice (Figure 4) showed that the colonic epithelial cells of the mice in the normal group were intact, and the goblet cells were neatly arranged. DSS destroys the integrity of the colonic mucosa tissue, the crypt structure and goblet cells are reduced, and there are severe ulcers and inflammatory cell infiltration in the colon. After intragastric administration of AX and HFY06, the structure of colonic epithelial cells remained destroyed, and the goblet cells were reduced, but the degree of inflammation was less than that in mice from the DSS group. In particular, the combined effect of AX and HFY06 showed that there was no obvious damage to the mouse colonic mucosa, there was an increase in goblet cells, the crypts were intact, and the integrity of the mucosal structure was effectively maintained.

Figure 4

Effect of AX combine L. fermentum HFY06 supplementation on H&E pathological of colon tissue in mice ((A) Normal, (B) Model, (C) L. fermentum HFY06, (D) AX, (E) L. fermentum HFY06 combined with AX). HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU), AX: 2.5%DSS with AX (200 mg/kg), AX+HFY06: 2.5% DSS with AX (200 mg/kg) and L. fermentum HFY06 (1.0 × 1010 CFU). Arrow 1 indicates inflammatory cell infiltration, arrow 2 indicates a reduction in goblet cells, and arrow 3 indicates colonic mucosal erosion.

Liver mRNA Expression in Mice

The NF-κB signaling pathway controls inflammation by regulating inflammatory and anti-inflammatory factors. As shown in Figure 5, the expression level of NF-κBp65, iNOS, COX-2, and TNF-α in the normal group was the lowest, and the expression level of IκB-α was the highest. After DSS induction, the expression of NF-κBp65, iNOS, COX-2, and TNF-α was significantly upregulated in the model group, while the expression of IκB-α was downregulated (p <0.05). After treatment with AX, HFY06, and the AX and HFY06 synergistic blend, the expression of NF-κBp65, iNOS, COX-2, and TNF-α was inhibited, while the expression of IκB-α was enhanced. Additionally, there was a greater combined effect of AX and HFY06 as compared to the effect of each single agent. The above results indicate that the synergistic reaction between AX and HFY06 can result in regulation of the expression of important transcription factors in the inflammatory response that inhibit inflammation, thereby alleviating local inflammation of the colon tissue.

Figure 5

Effect of AX combine L. fermentum HFY06 supplementation on mRNA expression levels in colon tissues ((A) NF-κBp65, (B) IκB-α, (C) iNOS (D) COX-2, (E) TNF-α). HFY06: 2.5% DSS with L. fermentum HFY06 (1.0 × 1010 CFU), AX: 2.5%DSS with AX (200 mg/kg), AX+HFY06: 2.5% DSS with AX (200 mg/kg) and L. fermentum HFY06 (1.0 × 1010 CFU). Different letters above the histogram indicate significant differences (P<0.05).

Discussion

Colitis is an unexplained inflammatory disease of the rectum and colon. It is an uncommon inflammation with a long course and is prone to recurrence, and it occurs frequently in many countries.20,21 It is difficult to cure with general drugs, and although many drugs have been used in the clinical treatment of colitis, they still produce side effects. Generally, patients tend to relapse after stopping the medication. Therefore, there has been great interest in safe microecological preparations with no side effects. Probiotics regulate the intestinal flora, and prebiotics provide nutritional substrates for probiotics.22,23 Studies have shown that the synbiotics formed by the combination of probiotics and prebiotics, such as those composed of Lactobacillus acidophilus, Lactobacillus rhamnosus, and inulin, can promote the balance of intestinal microecology and have a certain therapeutic effect on intestinal diseases.24 This can effectively alleviate the inflammation of the colon in mice and increase the proportion of beneficial bacteria in the intestine, but the effects of different probiotics in the treatment of colitis are very different. Liu et al found that Lactobacillus rhamnosus combined with inulin can reduce DSS-induced colitis, reduce pathological damage of colon tissue, reduce DAI score, regulate the expression of inflammatory cytokines, and have anti-inflammatory effects on mice with enteritis.25 Therefore, this study established a colitis animal test model to preliminarily explore the ability of a synbiotic composed of L. fermentum HFY06 and arabinoxylan to alleviate colitis.

In this study, we found that AX and L. fermentum HFY06 had significant effects on regulating mouse diarrhea, fecal occult blood, and weight loss in mice. The weight change in mice and the DAI score are two important indicators for evaluating the severity of colitis.26,27 The experimental results showed that the percentage of weight loss and the increase in the DAI score in mice mediated by DSS were significantly downregulated by AX and L. fermentum HFY06. Additionally, the synergistic effect of AX and HFY06 was greater than that of each alone. Histopathological observation revealed that DSS typically destroyed the submucosa and crypts, and the degree of inflammatory cell infiltration increased.28,29 However, there was a decrease in these pathological changes after the synergistic intervention of AX and HFY06. These results suggest that the synbiotic composed of AX and HFY06 has a protective effect on DSS-mediated colitis model mice. It was shown here for the first time that the synbiotic composed of AX and HFY06 exerts a strong protective effect on colitis.

The inflammatory response and oxidative stress are considered to be important pathological mechanisms that induce colitis, and the two regulate and complement each other.30 Oxidative stress plays a vital role in the pathogenesis of colitis, because the body’s own tissues can be attacked during the disease course. It can also activate inflammatory reactions by producing inflammatory substances through lipid peroxidation, leading to a sharp increase in inflammatory factors such as IL-6, IL-1β, and TNF-α, and a decrease in the level of IL-10.31 The amount of MDA can reflect the degree of tissue peroxidation damage, and the level of SOD enzymatic activity reflects the body’s ability to scavenge oxygen free radicals.32 MPO is a glycoprotein released by neutrophils when they encounter stimuli. After neutrophils are activated, they are released outside the cell or in the phagosome to promote a series of peroxidative stress responses and accelerate local intestinal inflammation.33 The results of the current study indicate that in mice with DSS-mediated colitis, serum SOD enzymatic activity decreased, NO and MDA levels increased, and MPO enzymatic activity increased in colon tissue, indicating that DSS intervention led to the occurrence of oxidative stress in the body. At the same time, it was also observed that a large number of pro-inflammatory factors (IL-6, IL-12, IL-1β, TNF-α, and IFN-γ) were produced in the serum of DSS-induced colitis mice, while the anti-inflammatory factor IL-10 decreased. After intragastric administration of AX and L. fermentans HFY06, inflammation and oxidative stress were alleviated, SOD enzymatic activity was significantly increased (p<0.05), NO and MDA were significantly decreased (p<0.05), MPO enzymatic activity was significantly decreased (p<0.05), pro-inflammatory factors IL-6, IL-1β, and TNF-α were suppressed, and anti-inflammatory factor IL-10 was increased. Similar studies have also found that the synbiotic composed of Lactobacillus rhamnosus strain GG and tagatose inhibits the regulation of pro-inflammatory cytokines and prevents the initiation of the inflammatory response, reducing the content of IL-6 and TNF-α.34 These results indicate that a synbiotic composed of AX and HFY06 can increase the activity of antioxidant enzymes, and decrease lipid peroxidation and the production of free radicals, thereby alleviating the body’s inflammatory response.

The NF-κB signaling pathway is a signal transduction pathway closely related to inflammation in the body. It has a regulatory effect on the expression of various pathogenic factors such as TNF-α, IL-6, IL-12, and some chemokines and inducible enzymes in the body that can cause colitis.35 Under normal circumstances, the cells are not stimulated, and NF-κB binds to its inhibitory protein IκB and is in an inactive state.36 When cells are subjected to external stimuli, such as DSS, the NF-κB signaling pathway is activated, and the rapid phosphorylation of IκB releases the bound NF-κBp65 protein. NF-κBp65 is phosphorylated and transferred into the nucleus to regulate the transcription of genes in the nucleus, including IL-1β, IL-6, COX-2, iNOS, and growth factors.37,38 Many studies have shown that the NF-κB signaling pathway plays an important role in affecting immune and inflammatory factors.39,40 Therefore, it is necessary to further explore the pathogenesis of NF-κB in colitis.

In the current study, the PCR results showed that the mRNA expression of NF-κBp65 in DSS-mediated colitis mice increased, while the mRNA expression of IκB-α decreased, and the NF-κB signaling pathway was activated. The synbiotic composed of AX and HFY06 inhibited the mRNA expression of NF-κBp65 and increased the mRNA expression of IκB-α, thereby inhibiting the activation of the NF-κB signaling pathway. In addition, because the NF-κB pathway was inhibited, the transcription of inflammatory genes in colon tissue was affected, and the mRNA expression of TNF-α, iNOS, and COX-2 was subsequently inhibited. This indicates that the synbiotic composed of AX and HFY06 may alleviate colitis through the NF-κB signaling pathway.

Conclusion

This study demonstrated for the first time that a synbiotic composed of AX and L. fermentum HFY06 ameliorated symptoms of DSS-induced colitis. The synergistic effect of AX and L. fermentum HFY06 inhibited the activation of the NF-κB signaling pathway, reduced the body’s inflammatory response, and increased the antioxidant capacity. This study provides an experimental basis for the study of synbiotics in the treatment of colitis, and it is necessary to conduct further research on its mechanism.